Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAN-ICD study of oral vancomycin prophylaxis for prevention of recurrent Clostridioides difficile infection
2019-002677-57Phase 3Active
- Sponsor
- Dra. Julia Origüen Sabater
- Start
- Jun 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing Oral vancomycin prophylaxis with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2021; status: active.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2019-002677-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002677-57.